Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

DOI PDF 被引用文献3件
  • Simona Gatto
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
  • Greg Ball
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
  • Francesco Onida
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
  • Hagop M. Kantarjian
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
  • Elihu H. Estey
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.
  • Miloslav Beran
    From the Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston; and the Center for Professional Excellence, The Methodist Hospital, Houston, TX.

抄録

<jats:title>Abstract</jats:title><jats:p>Prospective analysis of the importance of the plasma levels of β-2 microglobulin (B2M) in 553 patients with myelodysplastic syndrome (MDS) found that B2M is an independent prognostic variable for survival with weighted significance second only to the karyotype. The incorporation of the B2M covariate into risk assessment of MDS patients added significantly to the power of the IPSS to stratify MDS patients into risk categories. Our results further document that the 2 objectively measured covariates that display the highest power to predict survival, that is, karyotype and B2M, can alone be used for risk stratification. While the results must be verified in an independent and comparable population, our data strongly recommend routine measurement of B2M in patients with MDS.</jats:p>

収録刊行物

  • Blood

    Blood 102 (5), 1622-1625, 2003-09-01

    American Society of Hematology

被引用文献 (3)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ